Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026)....
Dupixent approved in Singapore as the first-ever biologic medicine for patients with COPD
Following recent approvals in the EU, US and China, the Singapore approval is based on two replicate phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and...